PCM
MYGN icon

Polymer Capital Management’s Myriad Genetics MYGN Stock Holding History

Polymer Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,795
Closed -$110K – 882
2025
Q2 		$110K Buy
20,795
+7,790
+60% +$46K 0.01% 582
2025
Q1 		$115K Sell
13,005
-38
-0.3% -$456 0.03% 469
2024
Q4 		$179K Buy
+13,043
New +$241K 0.05% 319

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Polymer Capital Management's MYGN Position: Q3 2025 in Review

Polymer Capital Management sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 20,795 shares — an estimated $110K sold.

Polymer Capital Management first reported a position in MYGN in Q4 2024 and held it in 3 quarters. The position peaked at $179K in Q4 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Polymer Capital Management reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Polymer Capital Management sold 20,795 Myriad Genetics shares in Q3 2025, an estimated $110K.
  • Polymer Capital Management first reported a position in Myriad Genetics in Q4 2024 and held it in 3 quarters.
  • Polymer Capital Management's Myriad Genetics position peaked at $179K in Q4 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Polymer Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.